369 related articles for article (PubMed ID: 23769759)
1. Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer.
Lowery WJ; Lowery AW; Barnett JC; Lopez-Acevedo M; Lee PS; Secord AA; Havrilesky L
Gynecol Oncol; 2013 Sep; 130(3):426-30. PubMed ID: 23769759
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
Lairson DR; Parikh RC; Cormier JN; Du XL
Value Health; 2014; 17(1):34-42. PubMed ID: 24438715
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
Havrilesky LJ; Pokrzywinski R; Revicki D; Higgins RV; Nycum LR; Kohler MF; Berchuck A; Myers ER; Secord AA
Cancer; 2012 Jan; 118(2):386-91. PubMed ID: 21598242
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
[TBL] [Abstract][Full Text] [Related]
5. Is centralization of ovarian cancer care warranted? A cost-effectiveness analysis.
Greving JP; Vernooij F; Heintz AP; van der Graaf Y; Buskens E
Gynecol Oncol; 2009 Apr; 113(1):68-74. PubMed ID: 19176236
[TBL] [Abstract][Full Text] [Related]
6. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Diaz-Montes TP; Gardner GJ; Giuntoli RL; Meisner BC; Frick KD; Armstrong DK
Cancer; 2007 Apr; 109(8):1513-22. PubMed ID: 17354232
[TBL] [Abstract][Full Text] [Related]
7. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
Wysham WZ; Schaffer EM; Coles T; Roque DR; Wheeler SB; Kim KH
Gynecol Oncol; 2017 May; 145(2):340-345. PubMed ID: 28291545
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial.
Fisher M; Gore M
Value Health; 2013 Jun; 16(4):507-16. PubMed ID: 23796284
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
11. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy.
Wallbillich JJ; Forde B; Havrilesky LJ; Cohn DE
Gynecol Oncol; 2016 Jul; 142(1):144-149. PubMed ID: 27106017
[TBL] [Abstract][Full Text] [Related]
12. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
13. Resource utilization for ovarian cancer patients at the end of life: how much is too much?
Lewin SN; Buttin BM; Powell MA; Gibb RK; Rader JS; Mutch DG; Herzog TJ
Gynecol Oncol; 2005 Nov; 99(2):261-6. PubMed ID: 16140364
[TBL] [Abstract][Full Text] [Related]
14. Resource implications of palliative chemotherapy for ovarian cancer.
Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
[TBL] [Abstract][Full Text] [Related]
15. Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost.
Patnaik A; Doyle C; Oza AM
Anticancer Drugs; 1998 Nov; 9(10):869-78. PubMed ID: 9890698
[TBL] [Abstract][Full Text] [Related]
16. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
18. Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?
Phippen NT; Leath CA; Miller CR; Lowery WJ; Havrilesky LJ; Barnett JC
Gynecol Oncol; 2013 Aug; 130(2):317-22. PubMed ID: 23707667
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
Barnett JC; Alvarez Secord A; Cohn DE; Leath CA; Myers ER; Havrilesky LJ
Cancer; 2013 Oct; 119(20):3653-61. PubMed ID: 23921967
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care.
Aziz F; Corder M; Wolffe J; Comerota AJ
J Vasc Surg; 2011 Nov; 54(5):1404-7. PubMed ID: 21741791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
